Drug intelligence / Profile preview

mk-6349

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules

Overview

MK-6349 is an experimental small molecule drug initially developed by Merck & Co. for the treatment of type 2 diabetes mellitus. It was investigated in clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with type 2 diabetes. The mechanism of action is unknown[4][2][3]. The highest development phase reached was Phase 1 before the program was terminated[2][3].

Beyond the preview

Go deeper on mk-6349.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mk-6349.

Explore the full profile